Form NRSRO-UPD FITCH RATINGS, INC.
Tweet
Share
E-mailSerious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Hercules Capital closes $325M notes offering due 2031
- Otsuka Receives FDA Approval for First-in-Class SIMTRIYO® (centanafadine) for the Treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in Adults and Pediatric Patients Aged 6 Years and Older
Create E-mail Alert Related Categories
SEC FilingsRelated Entities
Fitch RatingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
